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Transport system xc
  is a member of plasma membrane heterodimeric amino-acid transporters and consists of two protein
components, xCT and 4F2hc. This system mediates cystine entry coupled with the exodus of intracellular glutamate and regulates the
intracellular glutathione (GSH) levels in most mammalian cultured cells. We studied the activity of system xc
  and GSH content in
human ovarian cancer cell line (A2780) and its cisplatin (CDDP)-resistant variant (A2780DDP). The rate of cystine uptake was
approximately 4.5-fold higher in A2780DDP cells than in A2780 cells and the cystine uptake in A2780DDP cells was mediated by
system xc
 . Intracellular GSH content was much higher in A2780DDP cells but it fell drastically in the presence of excess glutamate,
which inhibited the cystine uptake competitively. xCT and 4F2hc mRNAs were definitely expressed in A2780DDP cells, but far less in
A2780 cells. Expression of system xc
  activity by transfection with cDNAs for xCT and 4F2hc made A2780 cells more resistant to
CDDP. Similar results on the cystine uptake were obtained in human colonic cancer cell lines. These findings suggest that the system
xc
  plays an important role in maintaining the higher levels of GSH and consequently in CDDP resistance in cancer cell lines.
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Cisplatin (cis-diaminedichloroplatinum (II), CDDP) is one of the
most widely used chemotherapeutic agents for the treatment of
human ovarian cancer and other tumours (Rosenberg, 1985).
CDDP is able to exert its cytotoxity to ovarian cancer via the
formation of intra- and interstrand CDDP-DNA adducts, which
can ultimately result in cell cycle arrest at G1, S, or G2-M and the
induction of genetically programmed cell death (Reed, 1998). One
of the major problems with CDDP treatment is the clinical
development of resistance to this drug (Perez et al, 1993).
Although the mechanisms underlying tumour resistance to CDDP
in vivo have not been understood clearly, in vitro studies on cell
lines have shown that they are multifactorial. These include
decreased drug transport, increased cellular detoxification because
of increased glutathione (GSH), changes in DNA repair involving
increased nucleotide excision repair and/or loss of mismatch
repair, increased tolerance of DNA adducts, and alterations in the
apoptotic cell death pathway (Andrews and Howell, 1990; Goto
et al, 1995; Johnson et al, 1997; Li et al, 1999, 2001). However, there
is abundant evidence showing that increase in GSH is a major
factor in CDDP resistance and several CDDP-resistant cell lines
keep the higher levels of GSH than the sensitive cell lines (Behrens
et al, 1987; Mistry et al, 1991; Godwin et al, 1992).
The biosynthesis of GSH occurs in two ATP-dependent
reactions (Meister, 1988). The first step is the synthesis of g-
glutamylcysteine (g-GC) from cysteine and glutamate catalysed by
g-glutamylcysteine synthetase (g-GCS). The second step is the
synthesis of GSH from g-GC and glycine catalysed by GSH
synthetase. g-GCS is the rate-limiting enzyme and the increase in
its activity results in the increase in intracellular GSH. It has been
shown that the activity of g-GCS is higher in CDDP-resistant cells
than in CDDP-sensitive cells and this may contribute to the high
GSH levels in the former cells (Goto et al, 1995; Yao et al, 1995;
Iida et al, 1999). Cysteine is an essential amino acid for many types
of mammalian cultured cells, but it is unstable in the extracellular
fluid, for example, in culture media and is rapidly autoxidised to
cystine (Toohey, 1975). Plasma membrane transport of amino
acids is mediated by several transport systems (Christensen, 1990).
We described previously in cultured mammalian cells an Na
+-
independent anionic amino-acid transport system, designated
system xc
 , highly specific for cystine and glutamate (Bannai and
Kitamura, 1980, 1981; Bannai, 1986). System xc
  is a heterodimeric
amino acid transporter consisting of two protein components
named xCT and 4F2hc (Sato et al, 1999, 2000). Cystine taken up via
system xc
  is rapidly reduced to cysteine, which is used for the
synthesis of GSH (Bannai and Ishii, 1982). Since intracellular
cysteine is a rate-limiting precursor for GSH synthesis, the
intracellular GSH level is regulated by the system xc
  activity. In
the present work, we have investigated the cystine transport
activity in the CDDP-resistant and CDDP–sensitive human
ovarian cancer cell lines.
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sMATERIALS AND METHODS
Cell culture
Human ovarian cancer cell line (A2780 and its CDDP-resistant
variant A2780DDP) and human colonic cancer cell line (HCT8 and
its CDDP-resistant variant HCT8DDP) were donated by Dr K J
Scanlon (Biochemical Pharmacology, City of Hope National
Medical Center, Duarte, CA, USA). They were cultured in RPMI
1640 supplemented with 5% fetal bovine serum at 371Ci n5 %C O 2.
The CDDP-resistant cells were treated with 100mM CDDP (Nihon
Kayaku Co., Tokyo, Japan) for 2h every week as described (Iida
et al, 1999).
Uptake of cystine
The uptake of cystine was measured by techniques described
previously (Bannai and Kitamura, 1980). Cells were plated at
5 10
5 in a 35mm diameter dish and cultured for 24h. They were
rinsed three times in warmed phosphate-buffered saline (pH 7.4)
containing 0.9mM CaCl2, 0.5mM MgCl2 and 5.6mM glucose
(PBSG). The cells were then incubated in 0.5ml of the prewarmed
uptake medium for 2min at 371C. The uptake medium was PBSG
containing [
14C]cystine (NEN Life Science Products Inc., Boston,
USA) (0.1mCi in 0.5ml). When Na
+ dependency of the uptake was
examined, the uptake of cystine was measured in an Na
+-free
medium, in which Na
+ was replaced by choline. The uptake was
terminated by rapidly rinsing the dish with ice-cold phosphate-
buffered saline and the radioactivity in the cells was counted. The
rate of uptake was determined under conditions approaching the
initial uptake rate, that is, by taking the values for the 2min uptake
of cystine. A portion of the cell lysate was used for determining the
radioactivity and another portion was assayed for protein.
Cytotoxicity of CDDP
The sensitivity of cells to CDDP was determined by dye exclusion
method using nigrosin (Patterson, 1979).
Determination of intracellular glutathione
The glutathione content was measured by enzymatic method
described previously (Bannai and Ishii, 1982), which is based on
the catalytic action of glutathione in the reduction of 5,50-
dithiobis(2-nitrobenzoic acid) by the glutathione reductase system
(Tietze, 1969). Cells were plated at 5 10
5 in a 35mm diameter
dish and cultured for 24h and total glutathione (GSH and GSSG)
was extracted with 5% trichloroacetic acid. The glutathione
extracted from the cells was mostly GSH and the content of the
oxidised form, GSSG, was negligibly low throughout this study.
Determination of intracellular cysteine
The cysteine content in the cells was determined by the method of
Cotgreave and Moldeus (1986) with slight modifications. Briefly,
the cells, plated at 5 10
5 in a 35mm diameter dish and cultured
for 24h, were rinsed three times with PBSG and incubated in the
dark at room temperature for 10min with 100mlo f8 m M
monobromobiamine in 50mM N-ethylmorpholine, pH 8, and
100ml of PBSG. Then 10ml of 100% trichloroacetic acid was added.
The protein precipitate was removed by centrifugation at 3000g
for 5min and aliquots were analysed for cysteine-bimane adducts
by HPLC. The HPLC separation was achieved on a steel column
(4.6mm 100mm) packed with 3mm octadodecylsilica reversed-
phase material purchased from Nacalai Tesque Inc., Kyoto, Japan.
The fluorescence at 480nm was monitored with the excitation at
394nm. The elution was performed with 9.0% (v/v) acetonitrile in
0.25% (v/v) acetic acid, pH 3.7, for 8 min, and then with 75% (v/v)
acetonitrile in water for 5min. The flow rate was 1mlmin
 1
throughout the process.
Northern blot analysis
Total cellular RNA was extracted using ISOGEN purchased from
Nippon Gene, Toyama, Japan. The cDNA probes for human xCT
and 4F2hc were labeled with [a-
32P]dCTP using RediprimetII
random prime labelling system from Amersham Pharmacia
Biotech (Little Chalfont, UK). Total RNA was electrophoresed on
a 1% agarose gel in the presence of 2.2 M formaldehyde, transferred
and hybridised as described previously (Sato et al, 1999).
Cell transfections
The inserts derived from mouse xCT and 4F2hc cDNAs were
produced by PCR reaction using the primers containing mutations
to generate appropriate restriction enzyme sites. The sequences of
the primers used for PCR were 50-CTCCTCAGATCTGACACTGC-
CATGG-30 and 50-GTATCTCAATCCTGGGCAGATGGCC-30 for
xCT, and 50-GCCTCACTGACTACAGATCTTGTCG-30 and 50-
GGAGGGTGGTAAGCTTTGCATAGGA-30 for 4F2hc. Both the
PCR products were cut out with BglII and HindIII and subcloned
into pEGFP-C1 (BD Biosciences Clontech, Palo Alto, CA, USA).
The sequences of the final constructs were verified by dideoxy-
nucleotide sequencing. Transient transfections were performed
using Lipofectamine Plust reagents (Invitrogen Corp., Carlsbad,
CA, USA) according to the manufacturer’s instruction. A2780 cells
were plated at 2.5 10
5 in a 35mM diameter dish and cultured for
24h. They were transfected for 3h in Opti-MEM
sI (Invitrogen
corp., carlsbad, CA, USA), and then the medium was changed to
RPMI 1640 with 5% fetal bovine serum and they were incubated
for further 33h.
RESULTS
Characterisation of the cystine transport
As shown in Figure 1, the rate of cystine uptake was approximately
4.5-fold higher in A2780DDP than that in A2780. To characterise
the transport system that mediates the cystine uptake, the rate of
cystine uptake was measured in the presence of various amino
acids in the uptake medium (Figure 1). In A2780 cells, the uptake
of cystine was not inhibited significantly by the amino acids tested.
In A2780DDP cells, the uptake of cystine was mostly Na
+-
independent and strongly inhibited by glutamate, but not by
aspartate, leucine or arginine. The uptake of cystine in A2780DDP
cells appeared to follow saturation kinetics with a Km of 0.06mM
whereas no saturation was found in A2780 cells (data not shown).
These results show clearly that the resistant cells acquire the
cystine transport activity mediated by system xc
 , which does not
occur in the sensitive cells.
Effect of CDDP on the cystine transport
In in vitro culture, CDDP resistance is not acquired with a single
treatment with CDDP but is acquired only after repeated exposure
to CDDP for a relatively long time. We examined an effect of CDDP
(up to 15mM) with a single treatment on the cystine uptake in the
CDDP-sensitive cells. The cells were incubated for 24h with
various concentrations of CDDP and the cystine uptake was
measured. The rate of uptake was not increased by the exposure to
CDDP (data not shown). Diethyl maleate (DEM) is an electrophilic
agent and is known to induce system xc
  activity (Bannai, 1984).
The rate of cystine uptake in A2780 cells was significantly
enhanced (about 1.7-fold increase) by DEM at a single exposure
and this enhanced uptake was inhibited by glutamate (data not
shown), suggesting that the enhanced uptake is mediated by
system xc
 . Then, A2780DDP cells were cultured without CDDP
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streatment for up to 6 months and the rate of cystine uptake was
measured. The rate of cystine uptake decreased slightly but
significantly after 6 months without CDDP treatment (Figure 2).
Glutamate was a potent inhibitor of the cystine uptake throughout
the experiment, indicating that A2780DDP cells preserve most of
the system xc
  activity for at least 6 months in the absence of CDDP
treatment. A2780DDP cells cultured without CDDP treatment for
6 months were tested to see whether they were still resistant to
CDDP. When they were incubated with 50mM CDDP for 24h,
viability was over 95% as judged by dye exclusion, which was
nearly equal to that in the control A2780DDP cells. A2780 cells
were heavily injured (approximately 5% viable) under such
conditions.
Intracellular GSH levels
A2780 and A2780DDP cells were incubated for up to 24h with
50mM of buthionine sulphoximine (BSO), which inhibits the GSH
synthesis, and the intracellular GSH was measured (Figure 3). The
intracellular GSH level before the incubation with BSO was 1.8-fold
higher (Po0.01) in A2780DDP (52.571.9nmol per mg protein)
than that of A2780 (28.972.1nmol per mg protein). The results are
consistent with those reported previously (Goto et al, 1995). GSH
decreased time dependently and the half-life of intracellular GSH
was estimated to be approximately 8–10h in both cells (Figure 3).
Changes in GSH level in the cells incubated for 24h with excess
amino acids were measured (Figure 4). Since cystine concentration
in RPMI 1640 is considerably high (0.2mM), we used cystine-
restricted RPMI 1640 (cystine¼0.05mM) to magnify a possible
effect of the amino acids. In A2780DDP cells, the GSH level
markedly decreased in the presence of excess glutamate but did
not decrease in the presence of excess aspartate or leucine. A slight
but significant decrease of an obscure origin was observed in the
presence of excess arginine. In A2780 cells, the GSH level did not
decrease even in the presence of glutamate. Then, A2780DDP cells
were cultured without CDDP treatment for 3 or 6 months, and the
intracellular GSH level was measured. The GSH level remained
unchanged during six months without CDDP treatment (data not
shown).
Intracellular cysteine levels
Intracellular cysteine level in A2780 and A2780DDP is shown in
Figure 5. It was much higher (about 4.2-fold) in the resistant cells
than in the sensitive cells. The result suggests that the high content
of intracellular GSH in A2780DDP cells is accounted for by the
increase in the intracellular content of cysteine, which is a rate-
limiting substrate for the GSH synthesis.
Expression of xCT and 4F2hc mRNAs
Expression of xCT and 4F2hc mRNAs in A2780 and A2780DDP
was examined by Northern blot analysis (Figure 6). xCT mRNA
was hardly detectable in A2780 cells, whereas it was clearly
expressed in A2780DDP cells. mRNA for 4F2hc was expressed in
both cells, although more strongly in the resistant cells. 4F2hc is
not only the component of system xc
  but also that of some other
heterodimeric amino-acid transporters (Palacin et al, 1998). IMR-
90 human fibroblasts exhibit very high system xc
  activity and are
employed as a positive control. The results clearly showed that
Figure 1 Na
+-dependency and inhibitory effect of amino acids on the
uptake of cystine in A2780 and A2780DDP cells. A2780 (open bars) and
A2780DDP cells (filled bars) were cultured in the dish for 24h and then
the rate of cystine (0.05mM) uptake was measured in the presence of
various amino acids (2.5mM), or in the absence of Na
+ ( Na
+). Values are
means7s.d. (n¼4). *Significantly below the corresponding control (Ctl),
Po0.05; **Po0.01. Figure 2 Uptake of cystine in A2780DDP cells cultured without CDDP.
A2780DDP cells were cultured without CDDP treatment (see Materials
and Methods) for 0, 3 and 6 months. They were plated in the dish and after
24h the rate of cystine (0.05mM) uptake was measured. Inhibitory effect of
glutamate (2.5mM) on the cystine uptake was also measured. Values are
means7s.d. (n¼6). *Significantly below control (0 month), Po0.05.
Figure 3 Changes in intracellular GSH levels of A2780 and A2780DDP
cells cultured with BSO. A2780 cells (open boxes) and A2780DDP cells
(filled boxes) were cultured in the dish for 24h and then the culture
medium was changed to the fresh medium containing 50mM BSO. They
were further cultured for the time indicated and the intracellular GSH levels
were determined. Values are means7s.d. (n¼4).
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ssystem xc
  was transcriptionally activated in the CDDP-resistant
cells.
CDDP resistance of A2780 cells with xCT expression
A2780 cells were transiently transfected with cDNAs of xCT and
4F2hc and the rate of uptake of cystine and CDDP resistance were
examined. As shown in Figure 7A, the rate of uptake in these
transfectant cells increased more than twice, and this increased
uptake was inhibitable by excess glutamate (data not shown). The
cells transfected with the cDNAs were significantly more resistant
to CDDP than the control cells (Figure 7B). However, the system
xc
  activity in these transfectants was much lower than that of
A2780DDP cells and concomitantly they were less resistant to
CDDP than A2780DDP cells. The viability of A2780DDP cells was
over 95% when they were incubated in 50mM CDDP for 24h.
Cystine transport activity in human colonic cancer cells
As shown in Figure 8, the rate of cystine uptake was also higher in
CDDP-resistant cells derived from human colonic cancer
(HCT8DDP cells) than that in the sensitive cells (HCT8 cells).
The cystine uptake in HCT8DDP cells was inhibited by glutamate.
In the colonic cancer cell lines, unlike the ovarian cancer cells,
inhibitory effect of glutamate was observed also in the sensitive
cells, indicating the significant occurrence of system xc
  in HCT8
cells, although its activity is much lower than that of HCT8DDP
cells.
DISCUSSION
Cystine is transported by system xc
  in the same ionic form as is
glutamate, that is, in an anionic form (Bannai and Kitamura, 1981).
Homocysteate and a-aminoadipate share the transport system but
aspartate is not a good substrate. Within physiological pH, cystine
occurs as a tetrapolar (neutral as a whole) ion in the main and as
a tripolar (anionic as a whole) ion for the rest and the latter
is the substrate for system xc
 . System xc
  is an exchange agency
and the physiologic flows via this system are the entry of cystine
Figure 4 Effect of various amino acids on intracellular GSH levels of
A2780 and A2780DDP cells. A2780 cells (open bars) and A2780DDP cells
(filled bars) were cultured in the dish for 24h and then the culture medium
was changed to the fresh medium, which was the cystine-restricted
(0.05mM) RPMI1640 with 5% fetal bovine serum and containing the amino
acid (10mM) indicated. The cells were further cultured for 24h and the
intracellular GSH levels were measured. Values are means7s.d. (n¼4).
*Significantly below control (Ctl), Po0.05; **Po 0.01.
Figure 5 Intracellular cysteine levels in A2780 and A2780DDP cells.
A2780 cells (open bars) and A2780DDP cells (filled bars) were cultured in
the dish for 24h and then the culture medium was changed to the fresh
one and after 24h the intracellular cysteine levels were measured. Values
are means7s.d. (n¼4). *Significantly greater than A2780, Po0.01.
Figure 6 Expression of xCT and 4F2hc mRNAs in A2780 and
A2780DDP cells. Twenty micrograms of total RNA isolated from A2780
cells and A2780DDP cells and 10mg of total RNA isolated from IMR-90
human fibroblasts were loaded. The hybridisation was performed as
described in Materials and Methods.
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sinto the cell coupled with the exit of glutamate from the cell
(Bannai, 1986). The cystine uptake through system xc
  is
competitively inhibited by the extracellular glutamate. Another
transport system for cystine identified in mammalian plasma
membrane is system b
0,+, which mediates an Na
+-independent
exchange of extracellular cystine and cationic amino acids against
intracellular neutral (dipolar) amino acids (Palacin et al, 1998).
The cystine uptake via this system is competitively inhibited by the
extracellular cationic amino acid. Ubiquitous transport systems for
neutral amino acids, systems A, ASC and L, usually mediate the
transport of dipolar form of the amino acids and cystine is far less
reactive with these systems. In the present study, characteristics of
the cystine uptake and the expression of xCT and 4F2hc mRNAs in
CDDP-resistant cells clearly showed that the cystine uptake in
these cells is largely mediated by system xc
 . As shown in Figure 1,
the cystine uptake in A2780DDP cells was not inhibited at all by
arginine indicating no contribution of system b
0,+. The CDDP-
sensitive A2780 cells also took up cystine, although the rate was
much lower than that of the resistant cells (Figure 1). The cystine
uptake in A2780 cells was not significantly inhibited by any of the
amino acids tested. Thus, neither system xc
  nor system b
0,+
mediated the cystine uptake in A2780 cells. At present a
transporter, if any, by which cystine is taken up in A2780 cells is
unidentified. In HCT8 cells, cystine transport activity was
significantly inhibited by glutamate (Figure 8), indicating the
occurrence of system xc
  in these cells, although the resistant
variant (HCT8DDP) had a much higher activity of this system.
In the present study, we have found a great increase of cystine
transport activity in CDDP-resistant cells (A2780DDP). In these
cells, the GSH levels were significantly higher than those in A2780
cells (Figures 3 and 4) and the drastic decrease in GSH by
glutamate, a competitive inhibitor of the cystine uptake, indicates
that system xc
  mainly contributes to the high level of GSH in
A2780DDP cells. When the GSH synthesis was inhibited by BSO,
the half-life of intracellular GSH was nearly equal in both cells
(Figure 3). This means that the difference of GSH content in the
CDDP-sensitive cells and the CDDP-resistant cells is mainly
accounted for by the difference of GSH synthesis rate. The
intracellular cysteine level was much higher in A2780DDP cells
than in A2780 cells (Figure 8) most probably because of the
enhanced uptake of cystine in the former cells. The concentration
of cysteine in A2780 cells and A2780DDP cells can be estimated to
be approximately 0.11 and 0.46mM, respectively, assuming that
1mg cell protein is equivalent to 5ml cell water. The reported value
for Km of g-GCS for cysteine is 0.35mM (Richman and Meister,
1975). Therefore, the rate of GSH synthesis depends almost linearly
on the intracellular cysteine level in both A2780 cells and
A2780DDP cells. The activity of g-GCS is about two-fold higher
in A2780DDP cells than in A2780 cells (Goto et al, 1995; Iida et al,
1999). It is, thus, reasonably concluded that the high GSH content
in CDDP-resistant cells results from the induction of both the
system xc
  transporter and the enzyme g-GCS and that the former
contributes more largely to the elevated GSH content than the
latter. Despite the considerable increase in both the transport and
the enzyme activities, GSH content in A2780DDP cells did not get
further than twice in A2780 cells (Figures 3 and 4). This may be
accounted for by a feedback inhibition of GSH synthesis by GSH.
Goto et al (1995) showed that the export of CDDP-GSH adduct was
elevated (about 20% increase) in the resistant cells. The value is
not large, yet the enhanced export may strengthen the CDDP
resistance associated with GSH.
In A2780 cells, the cystine transport activity was not induced by
a single exposure to CDDP. In contrast, the cystine transport
activity was induced significantly by DEM with the similar
treatment. It is obvious that the response to CDDP is quite
different from that to DEM. The system xc
  activity is induced by
electrophilic agents like DEM and reaches maximal level at about
48h (Bannai, 1984). The activity reverts to the original level within
2–3 days if the agent is withdrawn. In contrast, to acquire CDDP
resistance the cells are repeatedly treated with CDDP for a long
time (Timmer-Bosscha et al, 1993). Actually, the sensitive cells are
incubated with CDDP for 1h at a dose inducing approximately
90% cell death and subsequently cultured in fresh medium. After
cells are recovered, this treatment is repeated with a stepwise
increasing dose of CDDP. It takes about 3–4 weeks for the cell
recovery and a long period, about 1 year is required to obtain the
CDDP-resistant cell line. Presumably, the cells are selected and
acquire the stable and high expression of system xc
  during this
Figure 7 Uptake of cystine and CDDP resistance in A2780 cells
transfected with cDNAs for xCT and 4F2hc. A2780 cells were cultured in
the dish for 24h and then they were transfected with pEGFP-C1 (Control)
or cotransfected with pEGFP-C1/xCT and pEGFP-C1/4F2hc (xc
 ) using
Lipofectamine Plust. After transfection, the cells were incubated for 33h
and the rate of cystine (0.05mM) uptake was measured (A) or CDDP
resistance was examined (B). CDDP resistance was estimated by
measuring viability of the cells treated with 50mM CDDP in fresh medium
for the time indicated. Values are means7s.d. (n¼6). *Significantly greater
than the corresponding control, Po0.01.
Figure 8 Uptake of cystine in HCT8 and HCT8DDP cells. HCT8 cells
(open bars) and HCT8DDP cells (filled bar) were cultured in the dish for
24h and then the rate of cystine (0.05mM) uptake was measured in the
presence or absence of 2.5mM of glutamate. Values are means7s.d.
(n¼4). *Po0.01.
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slong and repeated exposure to CDDP. In some CDDP-resistant
ovarian cancer cell lines, a large number of genetic changes
probably associated with the development of CDDP resistance
were found (Wasenius et al, 1997). The enhanced system xc
 
activity may result from the genetic changes that occurred in
CDDP-resistant cells. Recently several genes, which are differen-
tially expressed in association with CDDP resistance, have been
identified (Johnsson et al, 2000). Among them the genes highly
expressed in the resistant cells include cytochrome oxidase I,
ribosomal protein 28S, elongation factor 1a, a-enolase, stathmin
and HSP70. The gene for xCT is a novel one and is worthy of note
in these studies hereafter.
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